The Food and Drug Administration (FDA) has granted Qualified Disease Product and Fast Track designation to NRX-101 for the treatment of complicated urinary tract infection (cUTI) and pyelonephritis.
Exblifep is a combination product that consists of cefepime, a cephalosporin antibacterial, and enmetazobactam, a beta-lactamase inhibitor. The Food and Drug Administration (FDA) has approved Exblifep ...
intravenous antibiotics Cefepime-enmetazobactam may be more effective than piperacillin-tazobactam in treating complicated UTI and acute pyelonephritis caused by organisms that produce ...
Compared with meropenem, cefepime-taniborbactam is superior for microbiologic and clinical cure of complicated urinary tract infection, including acute pyelonephritis. Cefepime-taniborbactam is more ...
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation ...
A young male cadaveric kidney transplant developed delayed graft function. In addition to fever, serial allograft biopsies revealed progressive infiltration of polymorphonuclear leukocytes. After ...
Researchers from Shaanxi Panlong Pharmaceutical Group Co. Ltd., Shaanxi Pioneer Biotech Co. Ltd. and affiliated organizations presented the discovery and preclinical characterization of novel ...
"The five factors with the highest odds of developing APN included obstructive and reflux uropathy, presentation to an acute care facility, urinary retention, history of UTI, and renal comorbidities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results